Donna LeBherz
About
In The Last Decade
Donna LeBherz
8 papers receiving 313 citations
Peers
Comparison fields: 5 of 45
- Radiology, Nuclear Medicine and Imaging 186
- Oncology 131
- Immunology 111
- Molecular Biology 92
- Hematology 48
Countries citing papers authored by Donna LeBherz
This map shows the geographic impact of Donna LeBherz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna LeBherz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna LeBherz more than expected).
Fields of papers citing papers by Donna LeBherz
This network shows the impact of papers produced by Donna LeBherz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna LeBherz. The network helps show where Donna LeBherz may publish in the future.
Co-authorship network of co-authors of Donna LeBherz
This figure shows the co-authorship network connecting the top 25 collaborators of Donna LeBherz. A scholar is included among the top collaborators of Donna LeBherz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donna LeBherz. Donna LeBherz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 12 | |
| 2 | 152 | |
| 3 | 47 | |
| 4 | 49 | |
| 5 | Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. | 29 |
| 6 | Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. | 32 |
| 7 | 2 | |
| 8 | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.